Advances in ocular allergy: basic mechanisms, clinical patterns and new therapies.
Ocular allergy presents unsolved mysteries in molecular and cellular mechanisms, and at the same time continues to challenge ophthalmologists daily in a wide array of disease forms. The recent understanding of the key role of the T helper type 2 cytokines, adhesion molecules and chemokines may provide future avenues for pharmacological targeting of releasable inflammatory mediators. More potent topical mast cell stabilizers and H1 receptor antagonists have become commercially available for the management of the prevalent and benign forms of allergic conjunctivitis. Immunostimulatory DNA sequences present an innovative and promising route for the treatment of ocular allergy, but clinical studies are needed to demonstrate their efficacy in humans. Surgical methods are suggested to reconstruct the ocular surface in the sight-threatening diseases vernal keratoconjunctivitis and atopic keratoconjunctivitis. This review presents an update of the major advances in both the basic mechanisms and clinical and therapeutic aspects of ocular allergic diseases that were reported during the past year.
Solomon
A
A
Department of Ophthalmology, Hadassah University Hospital, Jerusalem, Israel.
Pe'er
J
J
Levi-Schaffer
F
F
D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D003233:Conjunctivitis, Allergic / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology*; D005128:Eye Diseases / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D006801:Humans
D018926:Anti-Allergic Agents; D000893:Anti-Inflammatory Agents